Biosimilars reshape immunology care across EU a decade after market entry

11-06-2026

EURACTIV - The introduction of copycat versions of expensive biologic medicines has transformed treatment access for millions of Europeans living with immune-mediated inflammatory diseases, as cost savings from biosimilar competition are increasingly being reinvested into broader patient care. Read more